Text: Observer.com, Zou Xuchen, Editor: Lu Dong].
On February 4, Hepalink, which was defrauded by nearly 100 million yuan of electric fraud, announced a rectification report. Hepalink's wire fraud this time has also been evaluated by many industries as the largest amount of telecom fraud in the history of A-shares.
According to the Hepalink rectification report, the actual controller of Hepalink said that the wire fraud incident has entered the process of handling cases overseas, and it is expected that it will take a long time for the follow-up cases to be detected and the money recovered, in order to protect the rights and interests of all shareholders, especially small and medium-sized shareholders. The actual controller of Hepalink will advance funds worth no more than 11.74 million euros to the company in advance, and cooperate with the listed company to jointly recover the aforesaid amount.
According to Oriental Wealth, Hepalink's current share price is 763 yuan shares, compared with the opening price of 10 on January 1558 yuan shares, down 2788%, with a market value of 11.2 billion yuan as of press time.
Summary of Rectification Report, Data**: Hepalink Announcement.
Previously, on the evening of January 14, Hepalink issued an announcement saying that Hepalink's wholly-owned subsidiary, Techdow Pharma Italy Sr.l.(hereinafter referred to as "Tiandao Italy") recently encountered a criminal gang telecom fraud, involving an amount of about 1,170 million euros, equivalent to about 92 million yuan at that time.
At the same time, Hepalink said in the announcement on January 14 that after the incident, the company reported the case to the local government as soon as possible, and the case had been filed and the case investigation and handling had been carried out. At the same time, the company fully cooperates with the best work and strives to avoid losses to the greatest extent.
In terms of amount, Hepalink's net profit attributable to the parent company in the first three quarters of 2023 is only 14.3 billion yuan, this wire fraud is equivalent to 6426%。
On January 15, the Shenzhen Securities Regulatory Bureau issued a regulatory concern letter to Hepalink. The regulatory requirements of the Shenzhen Securities Regulatory Bureau include that Hepalink should set up a special working group, hire a third-party professional organization to conduct a comprehensive investigation of the incident if necessary, prudently assess the essence and impact of the incident, comprehensively sort out the problems and weaknesses in the internal control related to the control of the subsidiary, especially the overseas subsidiary, seriously rectify the problems found, clarify the accountability, and submit the investigation report and relevant supporting evidence reviewed by the board of directors to the Shenzhen Securities Regulatory Bureau.
On January 18, the Shenzhen Stock Exchange also issued a letter of inquiry to Hepalink. Include a detailed description of the process and latest progress of the defraud; Combined with the approval process for the payment of funds, the internal control procedures failed to effectively prevent the occurrence of Hepalink's alleged "telecom fraud".
Hepalink said in the inquiry reply letter that the criminals sent emails to the general manager of the Italian subsidiary by forging the email addresses of the company's executives, external lawyers and auditors, and set up ** on the grounds that the company was in the process of a highly confidential merger and acquisition, so that the general manager of the Italian subsidiary mistakenly believed that the matter was true and avoided the company's internal fund payment process according to the requirements of the criminals, and paid him a total of more than 1,170 euros.
According to the Financial Associated Press, although it is not uncommon for listed companies to encounter telecom fraud, such as BII Development, Shilong Industrial, Slack, Shenzhen Energy, etc., but in terms of the amount involved, Hepalink's wire fraud of 91.8 million yuan can be described as the highest amount in the history of A-shares.
Summary of the reply letter to the inquiry of the Shenzhen Stock Exchange, data**: company announcement.
On January 30, Hepalink released its 2023 performance forecast, and its estimated net profit attributable to the parent company is a loss of 9$2.4 billion to a loss of $64.7 billion yuan, compared with a profit of 7 in 20222.7 billion yuan, turning from profit to loss. Hepalink's main business includes the investment, development and commercialization of the entire heparin industry chain, biomacromolecule CDMO and innovative drugs.
Regarding the performance loss in 2023, in addition to the fraud of its wholly-owned subsidiary, Hepalink said in the announcement that the reasons include that the heparin industry continues to face the severe challenge of terminal destocking in 2023, the world's major heparin companies have generally slowed down the production pace, the order demand for heparin API has declined sharply, and the export data of China's heparin API has fallen far more than industry expectations year-on-year, and the company's API business has also been greatly impacted. At the same time, due to the impact of destocking, the company's preparation business in non-European and American overseas markets also showed a certain degree of decline.
2023 performance projection, data**: Hepalink announcement.
On February 2, the Shenzhen Securities Regulatory Bureau ordered Hepalink to take corrective measures. The Shenzhen Securities Regulatory Bureau stated in the relevant documents that after investigation, some of Hepalink's overseas subsidiaries had imperfect internal control systems and inadequate implementation in the daily management of bank accounts and online banking, the authorization and approval of fund payments, and the internal transfer of funds.
It is worth mentioning that the Shenzhen Securities Regulatory Bureau also stated in the relevant documents that Hepalink should notify the controlling shareholders and actual controllers of the relevant situation, and promote them to take active measures in accordance with laws and regulations to support the company to eliminate adverse effects, enhance the overall value of the company, and safeguard the legitimate rights and interests of small and medium-sized investors.
Hepalink stated in the rectification report that the company also established an independent third-party investigation team (hereinafter referred to as the "special investigation team") to conduct a comprehensive investigation of the incident, which was led by the company's independent directors and entrusted a leading international forensic investigation team to carry out the investigation with the cooperation of well-known international law firms. An independent verification report shall be formed and reported to the board of directors of the company no later than before the disclosure of the company's annual report, and shall be disclosed to the majority of investors at the same time.
This article is an exclusive manuscript of the Observer.com, and it is not allowed to be unauthorized and shall not be allowed.